360 related articles for article (PubMed ID: 29297903)
1. [Pembrolizumab for the treatment of melanoma: updates and perspectives.].
Chiarion Sileni V; Mandalà M; Queirolo P
Recenti Prog Med; 2017 Dec; 108(12):528-531. PubMed ID: 29297903
[TBL] [Abstract][Full Text] [Related]
2. [Combination strategies in melanoma therapy.].
Spagnolo F
Recenti Prog Med; 2017 Dec; 108(12):503-507. PubMed ID: 29297899
[TBL] [Abstract][Full Text] [Related]
3. The safety of anti PD-1 therapeutics for the treatment of melanoma.
Ramelyte E; Schindler SA; Dummer R
Expert Opin Drug Saf; 2017 Jan; 16(1):41-53. PubMed ID: 27737598
[TBL] [Abstract][Full Text] [Related]
4. Autoimmune Polyarthritis Induced by Cancer Immunotherapy With Checkpoint Inhibitor.
Quresh Q; Quinet R
J Clin Rheumatol; 2017 Jun; 23(4):235. PubMed ID: 28538282
[No Abstract] [Full Text] [Related]
5. Atrophic exocrine pancreatic insufficiency associated with anti-PD1 therapy.
Hoadley A; Sandanayake N; Long GV
Ann Oncol; 2017 Feb; 28(2):434-435. PubMed ID: 27864215
[No Abstract] [Full Text] [Related]
6. Evaluation of the pharmacokinetics and metabolism of pembrolizumab in the treatment of melanoma.
Longoria TC; Tewari KS
Expert Opin Drug Metab Toxicol; 2016 Oct; 12(10):1247-53. PubMed ID: 27485741
[TBL] [Abstract][Full Text] [Related]
7. Pembrolizumab and nivolumab: PD-1 inhibitors for advanced melanoma.
Ivashko IN; Kolesar JM
Am J Health Syst Pharm; 2016 Feb; 73(4):193-201. PubMed ID: 26843495
[TBL] [Abstract][Full Text] [Related]
8. The efficacy and safety of anti-PD-1/PD-L1 antibodies for treatment of advanced or refractory cancers: a meta-analysis.
Zhang T; Xie J; Arai S; Wang L; Shi X; Shi N; Ma F; Chen S; Huang L; Yang L; Ma W; Zhang B; Han W; Xia J; Chen H; Zhang Y
Oncotarget; 2016 Nov; 7(45):73068-73079. PubMed ID: 27683031
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of anti-programmed cell death-1 immunotherapy for skin carcinomas and melanoma metastases in a patient with xeroderma pigmentosum.
Salomon G; Maza A; Boulinguez S; Paul C; Lamant L; Tournier E; Mazereeuw-Hautier J; Meyer N
Br J Dermatol; 2018 May; 178(5):1199-1203. PubMed ID: 29274233
[TBL] [Abstract][Full Text] [Related]
10. Nivolumab and pembrolizumab as immune-modulating monoclonal antibodies targeting the PD-1 receptor to treat melanoma.
Faghfuri E; Faramarzi MA; Nikfar S; Abdollahi M
Expert Rev Anticancer Ther; 2015; 15(9):981-93. PubMed ID: 26313415
[TBL] [Abstract][Full Text] [Related]
11. Lupus-like cutaneous reaction following pembrolizumab: An immune-related adverse event associated with anti-PD-1 therapy.
Shao K; McGettigan S; Elenitsas R; Chu EY
J Cutan Pathol; 2018 Jan; 45(1):74-77. PubMed ID: 29028121
[TBL] [Abstract][Full Text] [Related]
12. Programmed Cell Death-1 Inhibitor-Induced Type 1 Diabetes Mellitus.
Clotman K; Janssens K; Specenier P; Weets I; De Block CEM
J Clin Endocrinol Metab; 2018 Sep; 103(9):3144-3154. PubMed ID: 29955867
[TBL] [Abstract][Full Text] [Related]
13. [Grover's-like drug eruption under anti-PD-1 therapy for metastatic melanoma].
Amini-Adle M; Balme B; Dalle S
Ann Dermatol Venereol; 2018 Dec; 145(12):802-803. PubMed ID: 30415933
[No Abstract] [Full Text] [Related]
14. Safety of pembrolizumab for the treatment of melanoma.
Martin-Liberal J; Kordbacheh T; Larkin J
Expert Opin Drug Saf; 2015 Jun; 14(6):957-64. PubMed ID: 25927979
[TBL] [Abstract][Full Text] [Related]
15. Pembrolizumab for the treatment of gastric cancer.
Kamath SD; Kalyan A; Benson AB
Expert Rev Anticancer Ther; 2018 Dec; 18(12):1177-1187. PubMed ID: 30280940
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy and targeted therapies in older patients with advanced melanoma; Young International Society of Geriatric Oncology review paper.
Bastiaannet E; Battisti N; Loh KP; de Glas N; Soto-Perez-de-Celis E; Baldini C; Kapiteijn E; Lichtman S
J Geriatr Oncol; 2019 May; 10(3):389-397. PubMed ID: 30025821
[TBL] [Abstract][Full Text] [Related]
17. Safety of pembrolizumab for resected stage III melanoma.
Pham F; Dalle S
Expert Opin Drug Saf; 2020 Oct; 19(10):1221-1227. PubMed ID: 32799585
[TBL] [Abstract][Full Text] [Related]
18. KEYNOTE-716: Phase III study of adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma.
Luke JJ; Ascierto PA; Carlino MS; Gershenwald JE; Grob JJ; Hauschild A; Kirkwood JM; Long GV; Mohr P; Robert C; Ross M; Scolyer RA; Yoon CH; Poklepovic A; Rutkowski P; Anderson JR; Ahsan S; Ibrahim N; M Eggermont AM
Future Oncol; 2020 Jan; 16(3):4429-4438. PubMed ID: 31870188
[TBL] [Abstract][Full Text] [Related]
19. Pembrolizumab joins the anti-PD-1 armamentarium in the treatment of melanoma.
Hersey P; Gowrishankar K
Future Oncol; 2015; 11(1):133-40. PubMed ID: 25572788
[TBL] [Abstract][Full Text] [Related]
20. Pembrolizumab for the treatment of melanoma.
Kumar SS; McNeil CM
Expert Rev Clin Pharmacol; 2015; 8(5):515-27. PubMed ID: 26146011
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
